Onconetix, Inc. Enters Loan Agreement to Fund Realbotix — $2.5M Advanced

What Happened

• On September 11, 2026, Onconetix, Inc. announced it entered into a Grid Promissory Note to make loans of up to $5.0 million to Realbotix, LLC. On that date, $2.5 million was advanced. The loans are unsecured and may be used by Realbotix for general corporate and working capital purposes.
• The Note matures September 11, 2027 and does not accrue interest until the earlier of (a) closing of the previously announced Share Exchange Agreement (dated February 11, 2026) under which Onconetix would acquire Realbotix, or (b) termination of that Share Exchange Agreement. If the Share Exchange Agreement is terminated, unpaid principal will accrue interest at 12% per year.
• Onconetix filed a Regulation FD press release about the loan on September 14, 2026.

Key Details

• Loan facility size: up to $5.0 million; initial advance: $2.5 million (Sept 11, 2026).
• Maturity: September 11, 2027; interest: none until closing or termination of the Feb 11, 2026 Share Exchange Agreement; 12% p.a. if Share Exchange Agreement is terminated.
• Security and guarantee: Note is unsecured; obligations guaranteed by Realbotix Corp. under a Guaranty dated Sept 11, 2026.
• Effect on Share Exchange Agreement: upon closing of the Share Exchange, the Note and all obligations will be cancelled and the Net Cash at Closing is increased by $500,000 plus the aggregate principal then outstanding under the Note. Closing is subject to customary conditions, including Onconetix having at least $12.5 million in Net Cash at closing.

Why It Matters

• This arrangement provides Realbotix with immediate working capital while preserving Onconetix's option to complete a previously announced share exchange (acquisition). For investors, the loan (and its cancellation terms on closing) ties short-term financing to the broader proposed transaction between the companies.
• Key investor considerations include the unsecured nature of the loan, the 12% interest backstop if the share exchange fails, the impact on Onconetix's reported cash and contingent obligations, and the closing condition requiring Onconetix to have at least $12.5 million in Net Cash.